Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Sarepta Therapeutics Inc (SRPT)

NASDAQ
Currency in USD
Disclaimer
115.00
-1.55(-1.33%)
Real-time Data

SRPT Comments

Archer Aviation 🥳
Are we going back to 100$?
90 $ very soon
120+ very soon
Huge Discount BUY BUY BUY!!!
Good timing
Target is 82$
this company is trash
On the 19th you said it will hit 100s, make up your mind
it will but looks like it will take 3 months. But I added 100 lots more.
I was hopeful it would bounce from the over reaction, bought at $91 after the dip...playing the long game now, but painful right now
Going big.
market is ********up right now. just wait couple months and it will hit 100s
Sell on the news
link?
115 !!!
Buy. Target 115-120$
arkg buy yesterday
The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations. The PDUFA goal date is Thursday, Feb. 25.
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full year 2020 financial results and to provide a corporate update.
Qwerty
Letsgoo
CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 26 individuals hired by Sarepta in January 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 20,565 shares of Sarepta's common stock, and in the aggregate, 7,760 restricted stock units (“RSUs”). The options have an exercise price of $89.40 per share, which is equal to the closing price of Sarepta's common stock on January 29, 2021 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlyi
about to take off... all aboard
2.7 million pump
sarepta is going back to the sky
pre-market is good, planning to rich TP on 208 this week
should be resistance at 208
 can you explain resistance at 208. Why would you say that?
 on 1h chart draw support & resistance levels starting from 08.01.21. It'll show what tomorrow after the market open need to TP if you are going short (it'll be about ± $104.5 per share)
this is will go back to his hight. with earning coming, it should break 100 easily soon
Let's pump to $120
I smell money
Can somebody explain this fall please?
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.